Key Takeaways
- • Blackstone and TPG are jointly marketing Hologic's surgical unit with a reported asking price of approximately $4 billion, according to Financial Times reporting cited in multiple sources.
- • The dual-sponsor approach by two major PE firms signals confidence in the asset's standalone valuation and marketability to institutional buyers in the medical device sector.
- • The sale process reflects renewed PE appetite for diagnostics and surgical device businesses, with valuations in the sector stabilizing enough to attract significant buyout capital.
- • Hologic's surgical unit divestiture aligns with broader portfolio optimization trends among healthcare conglomerates, particularly as medical device companies reassess core competency focus.
- • The $4B valuation underscores continued investor interest in healthcare infrastructure assets despite broader economic uncertainties in the medical technology market.
Summary
Blackstone and TPG are jointly seeking approximately $4 billion for the sale of Hologic's surgical unit, according to Financial Times reporting. The two prominent private equity sponsors are actively marketing the asset to potential acquirers in what represents a significant transaction within the medical device and surgical equipment space.
The joint sponsorship by Blackstone and TPG reflects strategic alignment between two of the industry's largest PE operators on this particular asset. The collaboration suggests confidence in the surgical unit's valuation and its appeal to a broader buyer pool, whether that includes strategic acquirers from within healthcare or alternative PE sponsors seeking exposure to the medical device sector.
The transaction comes amid renewed private equity activity in diagnostics and surgical equipment businesses. Multiple sources indicate that valuations in the broader healthcare diagnostics space have stabilized sufficiently to attract meaningful buyout capital, reversing earlier cycles of subdued PE interest. This renewed appetite reflects market recovery and perceived value opportunities in essential healthcare infrastructure assets.
The sale process is consistent with recent trends among diversified healthcare companies to optimize their portfolios by divesting non-core or specialized business units. Medical device and surgical equipment manufacturers have increasingly evaluated standalone operations that may operate more effectively under specialized ownership or operational management focused exclusively on their market segments.
For institutional investors and alternative investment professionals, this transaction size and sponsor involvement represents a meaningful data point on current valuation multiples and buyer appetite within the surgical device market, potentially informing broader assessments of healthcare technology M&A activity and PE deployment capital in 2026.
The joint sponsorship by Blackstone and TPG reflects strategic alignment between two of the industry's largest PE operators on this particular asset. The collaboration suggests confidence in the surgical unit's valuation and its appeal to a broader buyer pool, whether that includes strategic acquirers from within healthcare or alternative PE sponsors seeking exposure to the medical device sector.
The transaction comes amid renewed private equity activity in diagnostics and surgical equipment businesses. Multiple sources indicate that valuations in the broader healthcare diagnostics space have stabilized sufficiently to attract meaningful buyout capital, reversing earlier cycles of subdued PE interest. This renewed appetite reflects market recovery and perceived value opportunities in essential healthcare infrastructure assets.
The sale process is consistent with recent trends among diversified healthcare companies to optimize their portfolios by divesting non-core or specialized business units. Medical device and surgical equipment manufacturers have increasingly evaluated standalone operations that may operate more effectively under specialized ownership or operational management focused exclusively on their market segments.
For institutional investors and alternative investment professionals, this transaction size and sponsor involvement represents a meaningful data point on current valuation multiples and buyer appetite within the surgical device market, potentially informing broader assessments of healthcare technology M&A activity and PE deployment capital in 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.